What is it about?
Many authors have reported the presence of serum NMDAR antibodies in varying proportions of patients with schizophrenia; however, many others have not been able to confirm this. Because of the contradictory findings reported in various studies, we have investigated the NR1 subunit of NMDAR antibodies in patients with schizophrenia On the basis of this result, we conclude that the NR1 subunit of the NMDAR antibodies does not seem to have a role in schizophrenia.
Featured Image
Why is it important?
Studies reporting the presence of NMDAR antibodies in the serum, the rate of antibodies vary between 6% and 10% among patients with schizophrenia.These high rates should be confirmed in wider studies, which would then necessitate changes in the diagnosis and treatment protocols of schizophrenia.
Perspectives
Despite studies reporting seropositivity in the literature, NMDAR antibody was negative in both the patient and the control groups.
Dr Damla Timucin
Health Science University Van Training and Research Hospital
Read the Original
This page is a summary of: The role of NMDAR antibody in the etiopathogenesis of schizophrenia, September 2016, Dove Medical Press,
DOI: 10.2147/ndt.s113872.
You can read the full text:
Contributors
The following have contributed to this page
